// App-Quantinova.ai

3626 : CPX-351 Is Effective in Newly Diagnosed Older Patients with AML and with Multiple Risk Factors

Researchers

Presenter

  • Jorge E Cortes

Principal Investigators

  • Tibor Kovacsovics

  • Donna E. Hogge

  • Jonathan E. Kolitz

  • Martin S Tallman

  • Antje Hoering

  • Michael T. Chiarella

  • Arthur C. Louie

  • Eric Feldman

Medical Centers

  • Division of Hematology, University of British Columbia, Vancouver, BC, Canada

  • Portland, OR, USA,

Locations

  • United States

  • Canada

Companies

  • Celator Pharmaceutic

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • Alanine transaminase

  • Aspartate aminotransferase

  • Creatinine

Drug/Treatment

  • Daunorubicin

  • Cytarabine liposomal

  • daunorubicin + cytarabine

  • ara-c

Outcome

  • N/A

Study Design

  • randomized

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved